Exact(1)
Thirty-nine eyes with concomitant cataract and glaucoma who underwent phacotrabeculectomy (n = 20; 51.3%) or phacocanaloplasty (n = 19; 48.7%) were included into this trial on reduction of IOP, use of medication, success rate, incidence of complications and postsurgical interventions.
Similar(59)
In a quasi-randomised controlled trial (n = 61) the addition of biofeedback-assisted relaxation therapy to preventive medication did not increase the success rate at 3 years and, though the patients in the combined group were less likely to relapse, this finding did not reach statistical significance when subjected to an intention-to-treat analysis [46].
Interestingly, the success rate of medication was similar with 56%, [median in persistent AF 58% (IQR 16 61%); P = 0.57].
The surgical success rate (without medications, IOP ≤ 21 mmHg) was 83.33 % (20 eyes) and 72%% (18 eyes) in phacotrab group and phaco group respectively at 12 months.
In this group the success rate was 72%% (18 eyes) (without medications) and 100%% (with medications) respectively.
Efficacy end points evaluated in the extension phase were mean number of all CH attacks, pain intensity (range: no pain to very severe pain), treatment success rate, and use of rescue medication.
In this group the success rate was 83.33 % (20 eyes) (without medications) and 100%% (with medications).
Other benefits include physician satisfaction with images and decreased use of staff resources by increasing success rate based on appropriate screening and medication use.
These prescription medications have all been found to have a limited success rate and they are also associated with long term use side effects [ 2, 17].
However, a meta-analysis by Calkins et al. [ 13] revealed a single procedure success rate of 72% (on or off antiarrhythmic medication).
RFA is an invasive treatment, intended to cure AF, and has a success rate of 77% versus 52% for antiarrhythmic medication.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com